

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\073\2024-25
Date: 24.01.2025

B S E Limited,
P J Towers, Dalal Street,
Mumbai: 400001.
Scrip Code No.524394

National Stock Exchange of India Limited,
"Exchange Plaza", Bandra,
Kurla Complex, Bandra (E),
Mumbai – 400051.
Trading Symbol: VIMTALABS

Dear Sir/Madam,

Sub - Outcome of the Board Meeting.

Ref - Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to the subject cited above, we hereby inform you that the Board of Directors of the Company at their meeting held today have approved the following: -

1. Approved the unaudited standalone and consolidated financial results for the third quarter and nine- months ended 31st December, 2024, the same is enclosed along with Limited Review Report.
2. Appointment of Shri.Siva Rama Krishna Kambhampati as Chief Financial Officer of the Company w.e.f., 3rd March, 2025.

Copy of the unaudited standalone and consolidated financial results are also uploaded on the company's website i.e., <https://vimta.com/investors/financial-statements/> and the abridge version of the unaudited financial results along with Quick Response code (QR Code) and the details of the webpage where complete financial results are being published in the newspapers as per the provisions of the SEBI (LODR) Regulations, 2015.

The meeting commenced at 11:30 AM and ended at 02:30 PM. This is for your information and records.

Thanking you,

For **VIMTA LABS LIMITED**

Sujani Vasireddi
Company Secretary



Independent Auditor's Review Report on Standalone Unaudited Quarterly and year to date Financial Results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of VIMTA LABS LIMITED

1. We have reviewed the accompanying statement of unaudited standalone financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Company') for the quarter ended 31 December 2024 and the year to date results for the period C1 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.




4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 24-01-2025




for GATTAMANENI & CO.
Chartered Accountants
(Firm Regn.No.009303S)


G. SRINIVASARAO
Partner
ICAI Ms. No.210535

UPIN: 25210535BMYKB7819

Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months Ended December 31, 2024
(Amount in INR millions, except Earnings Per Share)

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31 Dec 24 (Unaudited)	30 Sep 24 (Unaudited)	31 Dec 23 (Unaudited)	31 Dec 24 (Unaudited)	31 Dec 23 (Unaudited)	31 Mar 24 (Audited)
1	Income from operations						
	(a) Revenue from operations (Refer note no. 5)	885.18	831.44	730.02	2,449.81	2,118.42	2,832.24
	(b) Other income	12.33	6.83	6.99	26.07	33.30	37.14
	Total Income	897.51	838.27	737.01	2,475.88	2,151.72	2,869.38
2	Expenses						
	(a) Cost of materials consumed and testing expenditure	201.65	179.94	148.64	522.15	434.51	565.48
	(b) Cost of lab setup (Refer note no. 5)	2.42	1.53	0.05	4.07	2.21	2.36
	(c) Changes in inventories of work-in-progress	-	-	0.15	-	0.40	1.04
	(d) Employee benefits expense (Refer note no. 6)	231.37	237.20	228.42	690.63	670.81	883.83
	(e) Finance costs	5.84	4.06	5.28	14.61	15.70	20.92
	(f) Depreciation & Amortisation expense	97.37	82.21	83.81	258.74	251.70	329.47
	(g) Other expenses	126.39	123.36	123.31	370.12	352.82	470.68
	Total Expenses	665.04	628.30	589.66	1,860.32	1,728.15	2,273.78
3	Profit/(Loss) before exceptional items and tax [1-2]	232.47	209.97	147.35	615.56	423.57	595.60
4	Exceptional items	-	-	-	-	-	-
5	Profit/(Loss) before tax from continuing operations [3-4]	232.47	209.97	147.35	615.56	423.57	595.60
6	Tax expense related to continuing operations						
	(a) Current tax	45.87	50.59	35.62	136.17	110.77	155.97
	(b) Taxes of earlier periods	(2.35)	-	-	(2.35)	3.82	5.42
	(c) Deferred tax (benefit)/expense	18.56	(4.17)	(4.01)	15.14	(23.02)	(31.88)
	Total Tax Expense	62.08	46.42	31.61	148.96	91.57	129.51
7	Profit/(Loss) for the period from continuing operations (5-6)	170.39	163.55	115.74	466.60	332.00	466.09
8	Profit/(Loss) before tax from discontinued operations(Refer note no. 8)	48.83	(18.35)	(21.37)	14.05	(63.71)	(80.23)
9	Tax expense related to discontinued operations	9.03	(0.67)	(0.18)	8.18	(1.77)	(2.21)
10	Profit/(Loss) for the period from discontinued operations [8-9]	39.80	(17.68)	(21.19)	5.87	(61.94)	(78.02)
11	Profit/(Loss) for the period from continued & discontinued operations [7+10]	210.19	145.87	94.55	472.47	270.06	388.07
12	Other Comprehensive Income/(expense), net of tax expenses						
	<i>Items that will not be reclassified subsequently to profit or loss :</i>						
	(a) Re-measurements of net defined benefit liability	(0.08)	(0.08)	(0.08)	(0.24)	(0.24)	(3.09)
	(b) Income tax relating to the items	0.02	0.02	0.02	0.06	0.06	0.78
	Total other comprehensive income/(loss), net of tax	(0.06)	(0.06)	(0.06)	(0.18)	(0.18)	(2.31)
13	Total Comprehensive Income for the period (comprising Profit/(Loss) and other Comprehensive income for the period [11+12])	210.13	145.81	94.49	472.29	269.88	385.76
14	Paid-up Equity Share Capital (Face value of Rs.2/- per equity share)	44.43	44.34	44.33	44.43	44.33	44.34
15	Other Equity						3,118.57
16	Earnings per equity share (EPS) from continuing operations (Face value of Rs.2 per share)						
	(a) Basic (INR)	7.65	7.38	5.22	21.01	14.98	21.04
	(b) Diluted (INR)	7.58	7.25	5.14	20.73	14.75	20.74
	(EPS for the quarter ended are not annualised)						
17	Earnings per equity share (EPS) from discontinued operations (Face value of Rs 2 per share)						
	(a) Basic (INR)	1.79	(0.80)	(0.96)	0.26	(2.79)	(3.52)
	(b) Diluted (INR)	1.77	(0.79)	(0.94)	0.26	(2.75)	(3.47)
	(EPS for the quarter ended are not annualised)						
18	Earnings per equity share (EPS) from continuing & discontinued operations (Face value of Rs.2 per share)						
	(a) Basic (INR)	9.44	6.58	4.26	21.27	12.18	17.52
	(b) Diluted (INR)	9.35	6.47	4.20	20.99	12.00	17.26
	(EPS for the quarter ended are not annualised)						



Notes to the results :

1. The above unaudited standalone financial results for the quarter and nine months ended December 31, 2024 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 24, 2025.
2. The results for the quarter and nine months ended December 31, 2024 were subjected to "Limited Review" by the statutory auditors of the company. An Unmodified report was issued by them thereon.
3. These unaudited standalone financials results of the Company are prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and the guidelines issued by the Securities and Exchange Board of India ("SEBI") in this regard.
4. The management has identified the reportable segments in accordance with the requirements of Ind AS-108 'Operating Segments', and decided that the Company has only one reportable segment, viz. 'Contract Research and Testing Services'.
5. The company has entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards Authority of India (FSSAI) on June 29, 2021 to setup, operate and transfer (SOT) a National food Testing Laboratory (NFL) in JNPT, Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has been considered as a "Service Concessionaire Arrangement" (SCA) and accordingly, revenue and costs are allocatable between those relating to lab setup services and those relating to operation and maintenance services. Further, the Company has acquired the right to charge the customer for the services to be rendered which has been assessed as an intangible asset.

Consequently, the amount of revenues from operations and lab setup expenses includes ₹ 2.42 million for the quarter ended December 31, 2024, ₹ 1.53 million for the quarter ended September 30, 2024, ₹ 0.05 million for the quarter ended December 30, 2023 and ₹ 2.36 million for the year ended March 31, 2024, respectively representing the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the right to charge the customer for the services to be rendered, respectively.

6. a) Pursuant to ' Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021)', the nomination and remunerations committee has granted 61,174 options to the eligible employees during its meeting held on January 24, 2025.
b) In respect of stock options granted pursuant to the Company's stock option plan, the fair value of the options is accounted as employee compensation expense over the vesting period. Consequently, the amount of employee benefits expense includes ₹ (2.49) million for the quarter ended December 31, 2024, ₹ 0.77 million for the quarter ended Septemembr 30, 2024, ₹ 3.04 million for the quarter ended December 31, 2023 and ₹15.53 million for year ended March 31, 2024 respectively.
7. The Board of Directors of the Company in their meeting held on March 30, 2024 considered and approved the proposed scheme of amalgamation ("scheme") wherein EMTAC Laboratories Private Limited a wholly-owned subsidiary of the company will be amalgamated with the Company under sections 230 to 232 and other applicable provisions of the Companies Act, 2013 read with the rules made thereunder. The aforesaid scheme is subject to the approval of shareholders and creditors of the respective companies, Stock Exchanges, National Company Law Tribunal and such other Authorities / regulators as may be required.

Further to the above, application for the Scheme of amalgamation has been filed with the Hon'ble National Company Law Tribunal (NCLT) on June 26, 2024 and subsequently, the NCLT has passed an order dated 10.07.2024, granting an exemption from holding the meeting of Equity Shareholders and secured and unsecured creditors of both the Holding Company and the Wholly owned Subsidiary Company in relation to the above-mentioned merger. The court has noted that the rights of unsecured creditors will not be adversely affected by the scheme of amalgamation.

The above proposed scheme has no impact on the standalone financials of the company for the quarter ended December 31, 2024.

8. The company vide Business Transfer Agreement (BTA) dated August 30, 2024 entered with Thyrocare Technologies Limited (Buyer) for sale and transfer of its Diagnostic and Pathological services business (Business) under slump sale, for a consideration of ₹ 70 million transferred the said Business to the buyer on October 11, 2024. In addition to the above consideration, the company through the Brand and Trademarks License Agreement (BTLA) with the buyer, will receive a Brand Royalty fee of 5% of the Revenue from this business over a period of at least 2 years from the date of actual transfer of business.

Details of discontinued operations

Amount in INR millions

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31 Dec 24 (Unaudited)	30 Sep 24 (Unaudited)	31 Dec 23 (Unaudited)	31 Dec 24 (Unaudited)	31 Dec 23 (Unaudited)	31 Mar 24 (Audited)
I. Total Income	7.20	69.19	72.88	145.18	229.04	299.63
II. Total Expenses	8.64	87.54	94.25	181.40	292.75	379.86
III. Profit/(Loss) before tax from discontinued operations [I-II]	(1.44)	(18.35)	(21.37)	(36.22)	(63.71)	(80.23)
IV. Tax expense related to discontinued operations	3.91	(0.67)	(0.18)	3.06	(1.77)	(2.21)
V. Profit/(Loss) after tax from discontinued operations [III-IV]	(5.35)	(17.68)	(21.19)	(39.28)	(61.94)	(78.02)
VI. Profit before tax on disposal of discontinued operations	50.27	-	-	50.27	-	-
VII. Tax expense related to discontinued operations	5.12	-	-	5.12	-	-
VIII. Profit after tax on disposal of discontinued operations [VI-VII]	45.15	-	-	45.15	-	-
IX. Profit/(Loss) from discontinued operations [V+VIII]	39.80	(17.68)	(21.19)	5.87	(61.94)	(78.02)

9. The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.

For and on behalf of the Board of Directors of

Vimta Labs Limited
CIN: U21107G1990PLC011977


Harita Vasireddi
Managing Director
DIN: 00242512

Place : Hyderabad, INDIA
Date : January 24, 2025



Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date Financial Results under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of VIMTA LABS LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of M/s VIMTA LABS LIMITED ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), for the quarter ended 31 December 2024 and the year to date results for the period 01 April 2024 to 31 December 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Financial Information performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

We also performed procedures in accordance with Circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), to the extent applicable.



4. The statement includes the results of the following entities:
- Vimta Labs Limited, the Holding Company
 - EMTAC Laboratories Private Limited, Wholly owned subsidiary
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 24-01-2025

for GATTAMANENI & CO.
Chartered Accountants
(Firm Regn.No.009303S)



G. SRINIVASARAO
Partner
ICAI Ms. No.210535

UDIN: 25210535BMYKC2773

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended December 31, 2024
(Amount in INR millions, except Earnings Per Share)

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31 Dec 24 (Unaudited)	30 Sep 24 (Unaudited)	31 Dec 23 (Unaudited)	31 Dec 24 (Unaudited)	31 Dec 23 (Unaudited)	31 Mar 24 (Audited)
1	Income from operations						
	(a) Revenue from operations (Refer note no. 5)	899.23	847.42	745.82	2,495.41	2,158.62	2,885.95
	(b) Other income	12.25	6.84	7.02	26.00	33.26	37.10
	Total Income	911.48	854.26	752.84	2,521.41	2,191.88	2,923.05
2	Expenses						
	(a) Cost of materials consumed and testing expenditure	203.88	181.95	151.21	528.63	440.23	573.17
	(b) Cost of lab setup (Refer note no. 5)	2.42	1.53	0.05	4.07	2.21	2.36
	(c) Changes in inventories of work-in-progress	-	-	0.15	-	0.40	1.04
	(d) Employee benefits expense (Refer note no. 6)	233.66	239.42	230.49	697.54	676.89	891.76
	(e) Finance costs	5.84	4.06	5.31	14.62	15.76	21.01
	(f) Depreciation & Amortisation expense	98.07	82.88	84.30	260.77	253.08	331.44
	(g) Other expenses	128.45	125.51	124.92	376.05	357.63	477.23
	Total Expenses	672.32	635.35	596.43	1,881.68	1,746.20	2,298.01
3	Profit/(Loss) before exceptional items and tax [1-2]	239.16	218.91	156.41	639.73	445.68	625.04
4	Exceptional items	-	-	-	-	-	-
5	Profit/(Loss) before tax from continuing operations [3-4]	239.16	218.91	156.41	639.73	445.68	625.04
6	Tax expense related to continuing operations						
	(a) Current tax	47.43	52.89	37.87	142.16	116.37	163.30
	(b) Taxes of earlier periods	(2.03)	-	-	(2.03)	3.82	5.42
	(c) Deferred tax (benefit)/expense	18.60	(4.13)	(3.97)	15.24	(2.03)	(31.79)
	Total Tax Expense	64.00	48.76	33.90	155.37	97.16	136.93
7	Profit/(Loss) for the period from continuing operations (5-6)	175.16	170.15	122.51	484.36	348.52	488.11
8	Profit/(Loss) before tax from discontinued operations (Refer note no. 8)	48.83	(18.35)	(21.36)	14.05	(63.71)	(80.23)
9	Tax expense related to discontinued operations	9.03	(0.67)	(0.18)	8.18	(1.77)	(2.21)
10	Profit/(Loss) for the period from discontinued operations [8-9]	39.80	(17.68)	(21.19)	5.87	(61.94)	(78.02)
11	Profit/(Loss) for the period from continued & discontinued operations [7+10]	214.96	152.47	101.32	490.23	286.58	410.09
12	Other Comprehensive Income/(expense), net of tax expenses <i>Items that will not be reclassified subsequently to profit or loss :</i>						
	(a) Re-measurements of net defined benefit liability	(0.08)	(0.08)	(0.08)	(0.24)	(0.24)	(3.11)
	(b) Income tax relating to the items	0.02	0.02	0.02	0.06	0.06	0.78
	Total other comprehensive income/(loss), net of tax	(0.06)	(0.06)	(0.06)	(0.18)	(0.18)	(2.33)
13	Total Comprehensive Income for the period (comprising Profit/(Loss) and other Comprehensive income for the period [11+12])	214.90	152.41	101.26	490.05	286.40	407.76
14	Paid-up Equity Share Capital (Face value of Rs.2/- per equity share)	44.43	44.34	44.33	44.43	44.33	44.34
15	Other Equity						3,152.62
16	Earnings per equity share (EPS) from continuing operations (Face value of Rs.2 per share)						
	(a) Basic (INR)	7.86	7.68	5.52	21.81	15.72	22.04
	(b) Diluted (INR)	7.79	7.54	5.45	21.52	15.49	21.72
	(EPS for the quarter ended are not annualised)						
17	Earnings per equity share (EPS) from discontinued operations (Face value of Rs.2 per share)						
	(a) Basic (INR)	1.79	(0.80)	(0.96)	0.26	(2.79)	(3.52)
	(b) Diluted (INR)	1.77	(0.79)	(0.94)	0.26	(2.75)	(3.47)
	(EPS for the quarter ended are not annualised)						
18	Earnings per equity share (EPS) from continuing & discontinued operations (Face value of Rs.2 per share)						
	(a) Basic (INR)	9.65	6.88	4.57	22.07	12.93	18.51
	(b) Diluted (INR)	9.56	6.76	4.50	21.78	12.73	18.24
	(EPS for the quarter ended are not annualised)						



Notes to the results :

- The above unaudited consolidated financial results for the quarter and nine months ended December 31, 2024 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on January 24, 2025.
- The results for the quarter and nine months ended December 31, 2024 were subjected to "Limited Review" by the statutory auditors of the company. An unmodified report was issued by them thereon.
- These unaudited consolidated financials results of the Company are prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and the guidelines issued by the Securities and Exchange Board of India ("SEBI") in this regard.
- The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 'Operating Segment' and states that the Group has only one reportable segment namely 'Contract Research and Testing Services'.
- The company has entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards Authority of India (FSSAI) on June 29, 2021 to setup, operate and transfer (SOT) a National food Testing Laboratory (NFL) in JNPT, Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has been considered as a "Service Concessionaire Arrangement" (SCA) and accordingly, revenue and costs are allocatable between those relating to lab setup services and those relating to operation and maintenance services. Further, the Company has acquired the right to charge the customer for the services to be rendered which has been assessed as an intangible asset.

Consequently, the amount of revenues from operations and lab setup expenses includes ₹ 2.42 million for the quarter ended December 31, 2024, ₹ 1.53 million for the quarter ended September 30, 2024, ₹ 0.05 million for the quarter ended December 30, 2023 and ₹ 2.36 million for the year ended March 31, 2024, respectively representing the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the right to charge the customer for the services to be rendered, respectively.

- Pursuant to ' Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021)', the nomination and remunerations committee has granted 61,174 options to the eligible employees during its meeting held on January 24, 2025.
 - In respect of stock options granted pursuant to the Company's stock option plan, the fair value of the options is accounted as employee compensation expense over the vesting period. Consequently, the amount of employee benefits expense includes ₹ (2.49) million for the quarter ended December 31, 2024, ₹ 0.77 million for the quarter ended September 30, 2024, ₹ 3.04 million for the quarter ended December 31, 2023 and ₹ 15.53 million for year ended March 31, 2024 respectively.
- The Board of Directors of the holding Company and its wholly-owned subsidiary, EMTAC Laboratories Private Limited in their meetings held on March 30, 2024 and March 29, 2024 respectively considered and approved the proposed scheme of amalgamation ("scheme") wherein EMTAC Laboratories Private Limited will be amalgamated with Vimta Labs Limited under sections 230 to 232 and other applicable provisions of the Companies Act, 2013 read with the rules made thereunder. The aforesaid scheme is subject to the approval of shareholders and creditors of the respective companies, Stock Exchanges, National Company Law Tribunal and such other Authorities / Regulators as may be required.

Further to the above, application for the Scheme of amalgamation has been filed with the Hon'ble National Company Law Tribunal (NCLT) on June 26, 2024 and subsequently, the NCLT has passed an order dated 10.07.2024, granting an exemption from holding the meeting of Equity Shareholders and secured and unsecured creditors of both the Holding Company and the Wholly owned Subsidiary Company in relation to the above-mentioned merger. The court has noted that the rights of unsecured creditors will not be adversely affected by the scheme of amalgamation.

The above proposed scheme has no impact on the consolidated financials of the company for the quarter ended December 31 2024.

- The company vide Business Transfer Agreement (BTA) dated August 30, 2024 entered with Thyrocare Technologies Limited (Buyer) for sale and transfer of its Diagnostic and Pathological services business (Business) under slump sale, for a consideration of ₹ 70 million transferred the said Business to the buyer on October 11, 2024. In addition to the above consideration, the company through the Brand and Trademarks License Agreement (BTLA) with the buyer, will receive a Brand Royalty fee of 5% of the Revenue from this business over a period of at least 2 years from the date of actual transfer of business.

Details of discontinued operations

Amount in INR millions


Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31 Dec 24 (Unaudited)	30 Sep 24 (Unaudited)	31 Dec 23 (Unaudited)	31 Dec 24 (Unaudited)	31 Dec 23 (Unaudited)	31 Mar 24 (Audited)
I. Total income	7.20	69.19	72.88	145.18	229.04	299.63
II. Total Expenses	8.64	87.54	94.25	181.40	292.75	379.86
III. Profit/(Loss) before tax from discontinued operations [I-II]	(1.44)	(18.35)	(21.37)	(36.22)	(63.71)	(80.23)
IV. Tax expense related to discontinued operations	3.91	(0.67)	(0.18)	3.06	(1.77)	(2.21)
V. Profit/(Loss) after tax from discontinued operations [III-IV]	(5.35)	(17.68)	(21.19)	(39.28)	(61.94)	(78.02)
VI. Profit before tax on disposal of discontinued operations	50.27	-	-	50.27	-	-
VII. Tax expense related to discontinued operations	5.12	-	-	5.12	-	-
VIII. Profit after tax on disposal of discontinued operations [VI-VII]	45.15	-	-	45.15	-	-
IX. Profit/(Loss) from discontinued operations [V+VIII]	39.80	(17.68)	(21.19)	5.87	(61.94)	(78.02)

- The previous periods figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.

For and on behalf of the Board of Directors of

Vimta Labs Limited

CIN: L24110TG1990PLC011977



Harita Vesireddi
Managing Director
DIN: 00242512

Place : Hyderabad, INDIA
Date : January 24, 2025

